Articles tagged with Simian Immunodeficiency Virus
A novel vaccine approach may have broken the impasse in developing an effective HIV vaccine by bypassing the usual path followed by vaccine developers. The technique, which uses gene transfer technology, protected monkeys from SIV infection and produced long-lived neutralizing activity.
Researchers estimated virus evolution using genetic sequences and found that SIV lineages giving rise to HIV-1 and HIV-2 date back to the 18th century. This finding challenges previous estimates of millions of years of coevolution between SIVs and their primate hosts.
A study led by Beth Israel Deaconess Medical Center demonstrates a T-cell-based HIV-1 vaccine strategy may be effective in fighting AIDS. The vaccine regimen induced potent immune responses, reducing viral replication and preventing AIDS development in monkeys.
A team of scientists found that sooty mangabeys have less immune system activation during SIV infection, explaining why they don't develop AIDS. This difference may hold key to understanding the mechanisms underlying AIDS progression in humans.
Scientists believe that HIV's lack of protection against immune system activation makes it more virulent in humans. Researchers are studying whether artificially disabling this protective function could make SIVs more pathogenic in their natural hosts.
A recent study published in The Journal of Immunology found that SIV infection in monkeys does not always lead to AIDS, contradicting current thinking. Researchers propose that host/virus co-adaptation enables monkeys to limit T cell immune activation and apoptosis, a mechanism that contributes to disease progression.
Research in African monkeys reveals that CD4 T-cell depletion is one part of a complex scenario leading to AIDS. Studies suggest that immune function can be preserved despite significant loss of mucosal CD4 T-cells.
Scientists studied SIVs in African green monkeys, finding a recent split that may have led to reduced virulence. This discovery sheds light on the potential course and timing of HIV evolution.
Chronic binge drinking in rhesus macaques accelerated SIV disease progression, increasing time to AIDS and viral loads. The study suggests that early treatment is crucial for reducing alcohol use and extending life among HIV-infected individuals.
Researchers found that a viral protein helps monkeys resist AIDS symptoms, but HIV-1 lacks this protective function, leading to increased immune activation and disease progression. The study suggests that treatments mimicking the primate immune system might offer a new approach to HIV therapy.
Researchers found that minocycline reduced brain cell damage, inflammation, and virus levels in SIV-infected monkeys, a potential breakthrough for treating HIV-related cognitive impairment. The antibiotic was able to calm down undefined biological pathways involved in neurodegenerative diseases.
Researchers traced how SIV spreads through the mouth, digestive tract, and lymph nodes after oral infection, identifying key tissues and organs infected. The findings may lead to a better understanding of early infection and the development of an effective HIV vaccine.
Researchers sequenced genetic material from a new strain of SIV in chimpanzees near Kisangani, Democratic Republic of Congo. The new strain is not related to HIV-1 and confirms that HIV-AIDS did not originate from oral polio vaccines.
Researchers found that alcohol consumption increased host susceptibility to SIV/HIV infection by increasing infectivity of cells and lymphocyte turnover. The study suggests that chronic or binge alcohol consumption may contribute to the risk of HIV infection, particularly through behavioral factors.
A study found that nearly 800 monkeys in Cameroon were infected with simian immunodeficiency viruses, highlighting the risk of human exposure through hunting and handling primates. The diversity among the viruses suggests a high degree of human exposure to SIVs.
Researchers have developed a new HIV vaccine that provides full protection against vaginal transmission of an HIV-like virus. The vaccine combines elements of the successful Sabin oral poliovirus vaccine with genetic fragments of the AIDS virus, triggering a robust immune response.
Researchers found that a Tat-specific killer T cell response can effectively contain simian immunodeficiency virus during early infection, leading to a massive immune response. The study suggests a new approach to designing HIV vaccines by stimulating immune responses against virus proteins produced within hours of infection.